You are here

Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at 2019 ASCO Genitourinary Cancer Symposium

-- Clinical study explored Calithera’s lead compound in combination with cabozantinib in patients with advanced renal cell carcinoma - -- Clinical study explored Calithera’s lead compound in combination with cabozantinib in patients with advanced renal cell carcinoma -
Saturday, February 16, 2019 - 06:00